while the GTG 'newsletter' has an enjoyable machiavellian nature, the one VERY interesting point was that they plan to list on Nasdaq in q4 this year.
It will be interesting to see how America values the company. I look at UK biotechs and feel they have unrealistically high valuations for non-profit making unproven drugs. GTG has astonishing (profitable) intellectual property in comparison. Plus they are saving some wallabies.
How can they go wrong?
(Maybe I shouldn't write when just home from the pub)
gtg newsletter/nasdaq plan
Add GTG (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.18M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.0¢ | 12.5¢ | $8.756K | 70.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4460 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 24060 | 2 |
View Market Depth
| Last trade - 13.15pm 09/05/2024 (20 minute delay) ? |
| GTG (ASX) Chart |